Atai Life Sciences N.V. ATAI
We take great care to ensure that the data presented and summarized in this overview for ATAI Life Sciences N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATAI
View all-
Walleye Capital LLC Plymouth, MN2.76MShares$3.29 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.72MShares$3.24 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$1.56 Million0.0% of portfolio
-
Brown University719KShares$855,0150.39% of portfolio
-
Two Sigma Investments, LP New York, NY717KShares$853,3850.0% of portfolio
-
Round Table Services, LLC704KShares$837,7600.46% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny648KShares$771,3410.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA411KShares$489,6650.0% of portfolio
-
Franklin Resources Inc San Mateo, CA356KShares$424,0640.0% of portfolio
-
Barclays PLC London, X0246KShares$292,4030.0% of portfolio
Latest Institutional Activity in ATAI
Top Purchases
Top Sells
About ATAI
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Insider Transactions at ATAI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 16
2024
|
Florian Brand |
SELL
Open market or private sale
|
Direct |
151,303
-31.52%
|
$151,303
$1.92 P/Share
|
Apr 02
2024
|
Sahil Kirpekar Chief Business Officer |
SELL
Open market or private sale
|
Direct |
35,801
-35.8%
|
$35,801
$1.85 P/Share
|
Apr 02
2024
|
Srinivas Rao |
SELL
Open market or private sale
|
Direct |
61,640
-35.22%
|
$61,640
$1.85 P/Share
|
Apr 02
2024
|
Anne Nagengast Johnson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,410
-27.14%
|
$27,410
$1.85 P/Share
|
Mar 14
2024
|
Florian Brand |
BUY
Exercise of conversion of derivative security
|
Direct |
350,000
+42.17%
|
-
|
Mar 14
2024
|
Srinivas Rao |
BUY
Exercise of conversion of derivative security
|
Direct |
175,000
+50.0%
|
-
|
Mar 14
2024
|
Sahil Kirpekar Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+50.0%
|
-
|
Mar 14
2024
|
Anne Nagengast Johnson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+49.75%
|
-
|
Nov 16
2023
|
Florian Brand |
BUY
Open market or private purchase
|
Direct |
20,000
+13.33%
|
$20,000
$1.16 P/Share
|
Sep 13
2023
|
Florian Brand |
BUY
Open market or private purchase
|
Direct |
40,000
+26.67%
|
$40,000
$1.45 P/Share
|
Mar 29
2023
|
Florian Brand |
BUY
Open market or private purchase
|
Direct |
70,000
+50.0%
|
$70,000
$1.48 P/Share
|
Mar 29
2023
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
1,214,297
+3.65%
|
$1,214,297
$1.32 P/Share
|
Apr 29
2022
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
21,900
+1.2%
|
$87,600
$4.47 P/Share
|
Apr 28
2022
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
34,700
+1.91%
|
$138,800
$4.46 P/Share
|
Apr 27
2022
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
19,803
+1.12%
|
$79,212
$4.64 P/Share
|
Apr 26
2022
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
46,207
+2.61%
|
$184,828
$4.69 P/Share
|
Apr 25
2022
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
8,961
+0.53%
|
$35,844
$4.78 P/Share
|
Apr 22
2022
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
52,820
+3.07%
|
$211,280
$4.83 P/Share
|
Apr 21
2022
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
68,688
+4.08%
|
$274,752
$4.95 P/Share
|
Apr 20
2022
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
67,703
+4.19%
|
$338,515
$5.09 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 725K shares |
---|---|
Open market or private purchase | 60K shares |
Open market or private sale | 276K shares |
---|